NeuroSense Therapeutics Announces Positive Initial Results from Phase 2 Trial of PrimeC for Alzheimer's Disease

Reuters09-11

NeuroSense <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Positive Initial Results from Phase 2 Trial of PrimeC for Alzheimer's Disease

NeuroSense Therapeutics Ltd., a biotechnology company specializing in treatments for severe neurodegenerative diseases, has announced promising initial results from its collaboration with NeuroKaire in the ongoing RoAD Phase 2 clinical trial. The trial is evaluating the drug candidate PrimeC for Alzheimer's disease. Utilizing NeuroKaire's proprietary technology, which converts blood-derived cells into neurons, the analysis of samples from Alzheimer's patients demonstrated that PrimeC treatment enhanced neuroplasticity, contributing to improved brain health and function. The trial also reported no treatment-related toxicity, indicating a favorable safety profile. Further analysis of PrimeC's cellular effects will continue in parallel with clinical outcomes from the RoAD trial. The trial's results will be presented at the CNS Summit 2025 in Boston, scheduled for November 2nd - 5th, by David Pattison, VP Business Development at NeuroKaire.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN70714) on September 10, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2566493989?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-11 02:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2566493989","market":"us","top_or_hot":-1,"title":"NeuroSense Therapeutics Announces Positive Initial Results from Phase 2 Trial of PrimeC for Alzheimer's Disease","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      NeuroSense <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Positive Initial Results from Phase 2 Trial of PrimeC for Alzheimer's Disease\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NeuroSense Therapeutics Ltd., a biotechnology company specializing in treatments for severe neurodegenerative diseases, has announced promising initial results from its collaboration with NeuroKaire in the ongoing RoAD Phase 2 clinical trial. The trial is evaluating the drug candidate PrimeC for Alzheimer's disease. Utilizing NeuroKaire's proprietary technology, which converts blood-derived cells into neurons, the analysis of samples from Alzheimer's patients demonstrated that PrimeC treatment enhanced neuroplasticity, contributing to improved brain health and function. The trial also reported no treatment-related toxicity, indicating a favorable safety profile. Further analysis of PrimeC's cellular effects will continue in parallel with clinical outcomes from the RoAD trial. The trial's results will be presented at the CNS <a href=\"https://laohu8.com/S/SMMT\">Summit</a> 2025 in Boston, scheduled for November 2nd - 5th, by David Pattison, <a href=\"https://laohu8.com/S/VP..UK\">VP</a> Business Development at NeuroKaire.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/NRSN\">Neurosense Therapeutics Ltd</a>. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN70714) on September 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NeuroSense Therapeutics Announces Positive Initial Results from Phase 2 Trial of PrimeC for Alzheimer's Disease</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeuroSense Therapeutics Announces Positive Initial Results from Phase 2 Trial of PrimeC for Alzheimer's Disease\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-11 02:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      NeuroSense <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Positive Initial Results from Phase 2 Trial of PrimeC for Alzheimer's Disease\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NeuroSense Therapeutics Ltd., a biotechnology company specializing in treatments for severe neurodegenerative diseases, has announced promising initial results from its collaboration with NeuroKaire in the ongoing RoAD Phase 2 clinical trial. The trial is evaluating the drug candidate PrimeC for Alzheimer's disease. Utilizing NeuroKaire's proprietary technology, which converts blood-derived cells into neurons, the analysis of samples from Alzheimer's patients demonstrated that PrimeC treatment enhanced neuroplasticity, contributing to improved brain health and function. The trial also reported no treatment-related toxicity, indicating a favorable safety profile. Further analysis of PrimeC's cellular effects will continue in parallel with clinical outcomes from the RoAD trial. The trial's results will be presented at the CNS <a href=\"https://laohu8.com/S/SMMT\">Summit</a> 2025 in Boston, scheduled for November 2nd - 5th, by David Pattison, <a href=\"https://laohu8.com/S/VP..UK\">VP</a> Business Development at NeuroKaire.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/NRSN\">Neurosense Therapeutics Ltd</a>. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN70714) on September 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NRSN","symbol_name":"Neurosense Therapeutics Ltd","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250910:nNDL397gb5:1","article_id":"2566493989","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2566493989","pubTimestamp":1757529028,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"NeuroSense Therapeutics Ltd., a biotechnology company specializing in treatments for severe neurodegenerative diseases, has announced promising initial results from its collaboration with NeuroKaire in the ongoing RoAD Phase 2 clinical trial. The trial is evaluating the drug candidate PrimeC for Alzheimer's disease. Utilizing NeuroKaire's proprietary technology, which converts blood-derived cells into neurons, the analysis of samples from Alzheimer's patients demonstrated that PrimeC treatment enhanced neuroplasticity, contributing to improved brain health and function. The trial also reported no treatment-related toxicity, indicating a favorable safety profile. Further analysis of PrimeC's cellular effects will continue in parallel with clinical outcomes from the RoAD trial. The trial's results will be presented at the CNS Summit 2025 in Boston, scheduled for November 2nd - 5th, by David Pattison, VP Business Development at NeuroKaire.Disclaimer: This news brief was created by Public ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NRSN":"Neurosense Therapeutics Ltd","BK4139":"生物科技"},"translate_title":"NeuroSense Therapeutics宣布PrimeC治疗阿尔茨海默病2期试验的积极初步结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NRSN":0.9},"content_text":"NeuroSense Therapeutics Announces Positive Initial Results from Phase 2 Trial of PrimeC for Alzheimer's Disease\n    \n\n        NeuroSense Therapeutics Ltd., a biotechnology company specializing in treatments for severe neurodegenerative diseases, has announced promising initial results from its collaboration with NeuroKaire in the ongoing RoAD Phase 2 clinical trial. The trial is evaluating the drug candidate PrimeC for Alzheimer's disease. Utilizing NeuroKaire's proprietary technology, which converts blood-derived cells into neurons, the analysis of samples from Alzheimer's patients demonstrated that PrimeC treatment enhanced neuroplasticity, contributing to improved brain health and function. The trial also reported no treatment-related toxicity, indicating a favorable safety profile. Further analysis of PrimeC's cellular effects will continue in parallel with clinical outcomes from the RoAD trial. The trial's results will be presented at the CNS Summit 2025 in Boston, scheduled for November 2nd - 5th, by David Pattison, VP Business Development at NeuroKaire.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN70714) on September 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2566493989","isCrawlerRequest":true}